Researchers aim to give new layer of protection to medical devices
NUI Galway and Queen’s University Belfast collaborate under Shared Island fund to tackle issue of hospital acquired infections.
Researchers at NUI Galway and Queen’s University Belfast are investigating how attaching sugar molecules to plastics could give medical devices a new layer of protection from infection.
The SUGARCOAT project is among 62 research collaborations supported by the Government’s Shared Island fund.
Early-career researchers Dr Joseph Byrne, NUI Galway, and Dr Matthew Wylie, Queen’s University Belfast, are working together to tackle the issue of hospital acquired infections associated with devices by taking preventative science to a new level.
The project is being supported with €193,000 from the Government’s Shared Island initiative.
The research team is supported by senior colleagues Professor Abhay Pandit, Director of CÚRAM, the SFI Research Centre for Medical Devices at NUI Galway, and Professor Colin McCoy, Head of School of Pharmacy in Queen’s University Belfast.
The team is attempting to harness the science behind the interaction of sugar molecules with bacterial proteins to make fluorescent materials which glow at first, darkening when they become compromised by bacteria. The technology would be attached to plastics which coat medical devices - such as urinary catheters or endotracheal tubes - allowing clinicians to spot potential infection at an early opportunity and react faster.
Dr Byrne, Honorary Research Lecturer in the School of Biological and Chemical Sciences, NUI Galway, explained the concept: “Prevention of bacterial infections is key to fighting the challenge of antimicrobial resistance and if this isn't possible, then early detection through innovative sensing materials could act as an alarm, allowing devices to be removed and replaced before infection becomes a more serious risk to patient health.”
Dr Wylie, Lecturer in Pharmaceutical Materials Science in Queens University Belfast, said: “Like many humans, sugar is something bacteria can’t resist getting a taste of. Many types of bacteria contain special proteins, which allow them to seek out and attach to sugar molecules, which they can use to grow and cause infection within the human body. Our new sugar-decorated coatings will exploit this interaction as an early warning, which has the potential to lead to the development of a new generation of medical devices, giving doctors and nurses tools to reduce risks of infection, bring down healthcare costs and decrease the need for antibiotic use in hospitals.”
Medical device-associated infections account for up to half of healthcare-associated infections and people who are immunocompromised people and those with cystic fibrosis (CF) are particularly at risk, with the island of Ireland having one of the highest number of people with CF per capita. These infections are a major health concern to patients and incur significant expense to healthcare systems, requiring longer stays and increased antibiotic usage. The rise of antimicrobial-resistant bacteria is an urgent problem, decreasing the effectiveness of existing antibiotics. It is estimated that across EU/EEA countries, 33,000 deaths per year in EU/EEA countries are associated with antimicrobial resistance, costing more than €1 billion to health services.
This project hopes to minimise the impact of this challenge by producing innovative coatings, which will prevent or detect bacterial build-up on widely-used medical devices before they lead to infection in a patient.
Dr Byrne, a CÚRAM collaborator, added: “Hospital-acquired bacterial infections are a major issue across the entire island of Ireland, and I’m excited to forge a new and lasting relationship with counterparts in Belfast to deliver meaningful new tools in fighting this challenge.
“The research allows me to combine my chemistry research with more patient-facing researchers and healthcare stakeholders to increase our societal impact. Building all-island collaborations through this scheme will help us to unlock Ireland’s potential for innovation and cutting-edge science.”
Dr Wylie added: “We are delighted to be able to pursue this innovative research under the Shared Island fund. Not only is it support for two early-career researchers, but it will open up opportunities for collaboration with industry and clinicians in both the North and South of Ireland, particularly as Galway is a global hub for major medical device companies and Queen’s has vast experience of collaborating with medical device companies across the UK and Ireland.”